1. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity
   Xin Zeng et al, 2019, Clinica Chimica Acta CrossRef
2. Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study
   Qing-jun Guo et al, 2020, Mediators of Inflammation CrossRef
3. Metformin Prevents Follicular Atresia in Aging Laying Chickens through Activation of PI3K/AKT and Calcium Signaling Pathways
   Jinwei Yao et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
4. Metformin turns 62 in Pharmacotherapy: emergence of non-glycaemic effects and potential novel Therapeutic applications
   Kingsley C. Mbara et al, 2021, European Journal of Pharmacology CrossRef
5. Effect of pioglitazone treatment on serum chemerin and vaspin levels in polycystic ovary syndrome.
   null Rana Hussein Kutaif et al, 2022, AJPS CrossRef
6. Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway
   Bo Xu et al, 2022, Endocr J CrossRef
7. Posttranslational modifications in pathogenesis of PCOS
   Huimei Wei et al, 2022, Front. Endocrinol. CrossRef
8. Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway
   Cheng Tong et al, 2022, Front. Endocrinol. CrossRef
9. SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model
   Manal Moustafa Mahmoud et al, 2023, Physiological Reports CrossRef
10. Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial
    Han Zhao et al, 2024, J Ovarian Res CrossRef